Short answer
SOLENO THERAPEUTICS INC (SLNO) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 8.01 (Other Events), Item 5.02 (Departure/Election of Directors or Officers). Jennifer Fulk appointed CFO effective ~March 2, 2026; succeeds James Mackaness, who retires by end of March: voluntary departure, no disagreement.
SOLENO THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jennifer Fulk appointed CFO effective ~March 2, 2026; succeeds James Mackaness, who retires by end of March: voluntary departure, no disagreement
- Fulk compensation: $525K base salary, 45% annual target bonus, stock options for 67,660 shares (4-yr vest, 1-yr cliff), 39,200 RSUs (4 equal annual installments)
- Strong CFO pedigree: 15+ years at Eli Lilly in senior finance roles, CFO of public company Talkspace (TALK), COO/CFO at 120Water
- Mackaness to stay as at-will employee through March 31, then consulting through December 31, 2026: equity continues vesting during consulting period, ensuring transition continuity
- Fulk covered under Key Executive Change in Control and Severance Plan filed January 23, 2026: downside protection in place from day one
Item 8.01 · Other Events
- CFO transition: Mrs. Fulk appointed as incoming CFO, Mr. Mackaness retiring from the role
- Effective date of transition tied to February 26, 2026 press release announcement
- Leadership continuity at CFO level is a key watch item for investors tracking SLNO's financial strategy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SOLENO THERAPEUTICS INC 8-K filings
Get the next SLNO 8-K as it lands
Follow SLNO for push alerts, or ask the research agent what this filing means.